Timing correction: Northrop Grumman is scheduled to release 2Q26 results today, Tuesday, July 21, 2026, before the U.S. market opens, followed by a 9:30 a.m. ET earnings call—not tomorrow. This preview reflects the pre-release setup and information available through the July 20 close.
Northrop enters 2Q with a favorable demand backdrop, a near-record $95.6 billion backlog, and several large multi-year growth vectors—B-21, Sentinel, weapons/solid rocket motors, missile defense, restricted programs, and space. The key debate is whether these opportunities are now converting into faster revenue growth, sustained margin improvement, and cash generation without creating new fixed-price program risk.
A modest headline beat alone may not be enough. Investors are likely to focus on:
The setup appears constructive but not unchallenging: NOC closed at $524.00 on July 20, down about 4.6% from its July 7 high of $549.04, though still above its $509.31 June 30 close. That suggests some cooling in near-term expectations, but the stock remains exposed to execution and guidance commentary.
| Metric | 2Q26 Street expectation | 2Q25 actual | Implied YoY change |
|---|---|---|---|
| Revenue | $10.8B | $10.35B | +4.4% |
| EPS | $6.83 | $8.15 | -16.2% |
The EPS comparison is not clean. Second-quarter 2025 GAAP EPS included a $1.04-per-share after-tax gain tied to the training-services divestiture. Accordingly, the expected year-over-year EPS decline should not be read as a like-for-like deterioration in operating performance.
Revenue is a more useful immediate scorecard. Management said after 1Q that it expected high-single-digit sequential sales growth in 2Q. From 1Q revenue of $9.88B, the Street’s $10.8B estimate implies roughly 9.3% sequential growth, placing consensus at the upper end of that framework.
Northrop reaffirmed the following full-year outlook after 1Q:
| 2026 guidance | Range | Midpoint |
|---|---|---|
| Sales | $43.5B–$44.0B | $43.75B |
| Segment operating income | $4.85B–$5.00B | $4.93B |
| MTM-adjusted EPS | $27.40–$27.90 | $27.65 |
| Free cash flow | $3.10B–$3.50B | $3.30B |
Segment expectations are for:
If NOC delivers the $10.8B revenue consensus in 2Q, first-half sales would be roughly $20.7B. Achieving the midpoint of full-year guidance would then require about $23.1B in the second half—only around 4% growth versus 2H25. In other words, the sales guide appears achievable; the larger question is whether management’s commentary supports upside beyond the current plan.
B-21 is the centerpiece. Management has described the program as nearing 10% of company revenue, with the recently agreed production-rate increase expected to improve long-term program economics.
Important facts entering the quarter:
What investors need to hear: no additional loss provisions, confidence in the LRIP estimate, evidence that capacity investments are on schedule, and clarity that the higher production rate is improving—not merely deferring—the program’s returns.
Aeronautics 2Q25 margins were 10.3%, a relevant comparison point. The segment posted 9.3% in 1Q26, largely because 1Q25 had contained the large B-21 loss provision, making the year-over-year comparison unusually favorable. The more meaningful test is whether margins trend toward the company’s low-to-mid-9% full-year target while B-21, TACAMO, and restricted-program volume rise.
Defense Systems should remain a principal growth engine. In 1Q, its organic sales grew 10%, driven by Sentinel, tactical solid rocket motors, and IBCS. Management expects Sentinel—currently about 6%–7% of company sales—to grow at a low-double-digit rate in 2026.
Key items to monitor:
The bullish outcome is strong Sentinel and munitions growth with margins around the company’s ~10% full-year guide. A weak outcome would be slower program conversion, lower EAC favorability, or signs that supply-chain capacity remains a gating item.
Mission Systems is NOC’s highest-margin major segment and has been a consistent source of upside. In 1Q, sales rose just 2%, but operating margin reached 15.1%, supported by favorable EAC adjustments and the absence of prior-year restricted-business investments.
For 2Q, investors should watch whether:
The 2Q25 comparison is demanding: revenue grew 14% and margin was 14.0%, helped by a restricted-award timing benefit. Solid underlying growth and a mid-teens margin would still support the thesis.
Space is the segment most likely to shape downside perception. It has been working through the wind-down of NGI and certain restricted-space work, while ramping SDA satellite programs and newer awards.
The immediate issue is the $71M unfavorable EAC adjustment taken in 1Q on GEM 63XL after a launch anomaly. Management said it reviewed the broader portfolio and did not identify another significant EAC issue, while maintaining its approximately $11B sales / 11% margin guidance.
For 2Q, investors should look for:
Space generated a 10.6% margin in 2Q25 despite a 12% sales decline. A return toward the 11% full-year margin guide would help establish that the first-quarter charge was isolated.
NOC generated negative $1.82B of free cash flow in 1Q, consistent with its historically back-end-loaded cash profile. Management reaffirmed $3.1B–$3.5B of full-year FCF despite raising planned 2026 CapEx to $1.85B.
The company has explicitly said that operating cash flow and CapEx are weighted toward the second half, especially the fourth quarter. Therefore, 2Q cash flow does not need to be exceptional. But investors will want evidence that:
A reaffirmation of cash guidance should be viewed positively. Any reduction would likely matter more than a small EPS variance because it would challenge the investment-and-return balance of the B-21 expansion.
NOC ended 1Q with $95.6B of backlog, essentially flat sequentially but near a company record, after $9.8B of awards. The quarter included $4.9B of restricted-program awards, plus awards for F-35, infrared countermeasures, and Triton.
The bar for 2Q is not necessarily a dramatic backlog increase; classified programs, timing of awards, and large contracts can make quarterly book-to-bill lumpy. Still, investors should seek:
The strategic demand picture remains compelling. The near-term risk is not demand scarcity, but rather the speed of contracting, supply-chain scaling, labor availability, and execution on high-consequence development and production programs.
NOC’s 2Q report should be evaluated as a proof-of-execution quarter. The strategic case—an unusually strong defense-demand environment and a portfolio exposed to the highest-priority U.S. and allied capabilities—is intact. But the stock needs confirmation that Northrop can translate that demand into accelerating revenue, stable program economics, and cash flow while funding a major B-21 industrial expansion.
The most important combination for investors would be:
~$10.8B or better revenue, clean B-21 and GEM 63XL execution, sustained Mission Systems profitability, healthy bookings, and an unambiguous reaffirmation of 2026 sales, margin, EPS, and FCF guidance.